A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Advanced Gastrointestinal Cancer Clinical Trial

Official title:
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Status Completed

Clinical Trial Summary

Clinical Trial Description

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02024607
Study type	Interventional
Source	Sumitomo Pharma America, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 2014
Completion date	November 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02008539` - Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101	Phase 1/Phase 2
Completed	`NCT01912131` - Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients	N/A
Completed	`NCT02760199` - 89Zr-AMG211 PET Imaging Study	Phase 1
Completed	`NCT02677129` - Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy	N/A